Healthcare
Actinogen Medical Limited(ATGGF)
Live Price
Offline$0.0008
+0.00% today
1Y Change
-96.00%
Window
Jun 27, 2025 โ Jun 25, 2026
- Market Cap
- $170.00M
- Revenue Growth
- -44.7%
- EPS Growth
- +18.3%
- Dividend Yield
- 0.0%
Coverage: 254 bars ยท Jun 27, 2025 โ Jun 25, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Actinogen Medical Limited (ATGGF) is a Healthcare stock with a market cap of $170.00M and listed on OTC. The stock last traded around $0.00 and down 96.0% across the available one-year price window (Jun 27, 2025 โ Jun 25, 2026). Baseline metrics include revenue growth of -44.7%, EPS growth of +18.3%, a dividend yield of 0.0%. What stands out right now is revenue -44.7%, EPS +18.3%, free cash flow +55.2% with operating margin -365.3% and ROIC -211.3%. Valuation already assumes a fairly strong business story at price/sales 30.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ATGGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-44.7% vs +7.6% peer median
Operating Margin
Below sector median
-365.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Feb 25, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -44.7% and EPS is at +18.3%, with operating margin around -365.3%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 31, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 25, 2026 | โ | +0.0% | +0.0% | +28.6% |
2025 Aug 31, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Feb 24, 2025 | โ | +0.0% | +0.0% | +25.0% |
Benchmark Edge
ATGGF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ATGGF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ATGGF Max Drawdown
-98.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ATGGF and SPY.
Company Overview
Actinogen Medical Limited
Other OTC
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ร-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
- Leadership
- Steven G. Gourlay
- IPO Date
- Sep 18, 2018
- Employees
- 6
- Street Address
- 109 Pitt Street
- Mailing
- Sydney, NSW, 2000
- Region
- Sydney, NSW, AU
- Reporting Currency
- USD
- Investor Line
- 61 2 8964 7401
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 30.7
- Price/Book
- 17.9
Growth
- Revenue
- -44.7%
- EPS
- +18.3%
- Free Cash Flow
- +55.2%
Profitability
- Gross Margin
- 96.2%
- Operating Margin
- -365.3%
- Net Margin
- -326.3%
- ROE
- -134.1%
- ROIC
- -211.3%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 4.19
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.